Casey McDonald

The Alliance for Clinical Research Excellence and Safety (ACRES) is advocating a “systems thinking” approach in efforts to meet increasing demands to standardize and integrate support for trial sites.

Casey McDonald previews pharma’s Oscars, the Prix Galien USA Awards, which this fall will bring some red carpet glamor and, hopefully, cheer to the industry.

September 28, 2015.

A slightly different take on this Turing Pharmaceuticals/Martin Shkreli business?

UNITE HERE, a labor union representing 270,000 workers people across Canada and the US, is has questioned pharma’s connections to the influential and highly visible American Heart Association (AHA). Casey McDonald reports.

September 16, 2015.

Free speech ruling, social media flap, and "female Viagra" highlight busy month for agency.

A patient has been prescribed a drug, your company’s drug. What next? Is there an app for that?Step back and think about the patient journey to this point. In the course of the joys and trials of day-to-day living, a patient may be afflicted with early symptoms. Be they minor or severe, a patient hopefully receives a diagnosis, often after missed opportunities and wrong turns than can stretch for years.

Alzheimer’s disease (AD) researchers have seen more than their share of hopefulness and disillusionment over the years. Recent apparent gains targeting one of the disease’s two molecular bull’s-eyes may have reinvigorated drug development, or it may have set developers and investors up for letdown once more. To follow the news coming out of July’s Alzheimer’s Association International Conference in Washington, one had to be prepared for both glass half-full and half-empty interpretations.

The American Medical Association invested heavily in DC influence in the first two quarters of 2015. PhRMA wasn't far behind. Casey McDonald reports.

Amgen and Sandoz received a decision from the U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday. PharmExec spoke with legal and biosimilar experts for their initial reactions.

Finding the R&D sweet spot.

Masters of the deal converge in New York to discuss the status of their trade and the forces propelling M&A, licensing, and partnerships in the life sciences for 2015.

Casey McDonald presents some highlights from a blustery few days in Chicago, with immunotherapy and cost, predictably taking center stage.

May 31, 2015.

The World Medical Innovation Forum unveils its inaugural list of breakthrough neuroscience technologies. We highlight a few here.

A hot commodity, the FDA’s Rare Pediatric Disease Priority Review Voucher program once again proved its worth, with today’s $245m transaction.

May 19, 2015.

Casey McDonald reports on yesterday's Healthcare Businesswoman’s AssociationWoman of the Year award ceremony in New York

Casy McDonald looks forward to CBI's Patient Adherence and Access Summit in Philadelphia.

Neuroscience luminaries clamored onto the stage at this week's World Medical Innovation Forum in Boston to present the meeting’s much-anticipated "Disruptive Dozen".

Pricing and Sovaldi couldn’t avoid mention at this week’s World Medical Innovation Forum put on by Partners Healthcare in Boston. The meeting highlighted multiple issues in neuroscience but also touched on hot buttons across the industry.

Although the strategic hurdles of biosimilars market entry are not new, the task of imitating substantially more complex molecular entities offers up a host of new operational questions for pharma.

Is it time to view cell therapy companies differently on Wall Street-even distinct from biotech?

Although the strategic hurdles of biosimilars market entry are not new, the task of imitating substantially more complex molecular entities offers up a host of new operational questions for pharma.

March 12, 2015.

Pharm Exec profiles patient DNA partnering advocate 23andMe, which recently struck data deals with a pair of big Pharmas, thrusting the debate over personal genomics and patient treatment back into high gear.

In reaction to AbbVie’s massive acquisition of Pharmacyclics, investors who were caught unprepared are looking for ways they could have predicted the deal. Casey McDonald looks at the reaction on Twitter.

The cholesterol-fighting market is back with a vengeance; plenty of complications in store

The interesting dynamic of industry-targeted memes in social media-still a quiet treading ground for pharmas.